Lantus FAERS Safety Signals: What Post-Market Surveillance Reveals About Insulin Glargine

How FAERS Works and Why It Matters for Lantus

The FDA Adverse Event Reporting System collects voluntary reports of suspected medication side effects from patients, clinicians, and manufacturers. FAERS does not prove causation. It detects statistical "signals" that warrant further investigation through controlled studies or label changes.

For a drug prescribed to millions of people with diabetes, FAERS data accumulates rapidly. Insulin glargine has been on the U.S. market since April 2000, giving regulators over two decades of post-market exposure data. The sheer volume of reports (exceeding 100,000 cumulative entries) reflects both widespread use and the inherent risks of injectable insulin therapy. FAERS queries using the openFDA API show that Lantus ranks among the most-reported insulin products, though raw report counts must be interpreted against prescription volume. A drug used by 8 million patients will naturally generate more reports than one used by 80,000.

The FDA's Office of Surveillance and Epidemiology reviews FAERS data quarterly using disproportionality analyses, including the Empirical Bayesian Geometric Mean (EBGM) and Proportional Reporting Ratio (PRR). When a drug-event combination exceeds predefined thresholds, a safety signal is generated. For insulin glargine, several signals have triggered regulatory action or formal investigation since launch. The FDA's Sentinel System now supplements FAERS with active surveillance using electronic health records and claims data from over 100 million patients, providing a second layer of pharmacovigilance that addresses FAERS limitations like underreporting and missing denominators [1].

Hypoglycemia: The Persistent Leading Signal

Hypoglycemia accounts for the largest share of Lantus FAERS reports and remains the primary safety concern on the current prescribing label. Severe hypoglycemia (blood glucose <54 mg/dL with neuroglycopenic symptoms) carries real clinical consequences: falls, cardiac arrhythmias, seizures, and death in rare cases.

FAERS data consistently flags three hypoglycemia subtypes for insulin glargine. Nocturnal hypoglycemia appears at a lower rate than with NPH insulin, a finding confirmed by randomized trials, but still generates substantial reports. The Treat-to-Target trial (N=756) demonstrated that glargine produced 25% fewer confirmed nocturnal hypoglycemic episodes compared to NPH when both were titrated to the same fasting glucose target of <100 mg/dL [2]. Severe hypoglycemia requiring third-party assistance constitutes approximately 8-12% of hypoglycemia-related FAERS entries for glargine. And hypoglycemic unawareness, where patients lose adrenergic warning symptoms after recurrent lows, appears in a subset of reports associated with longer insulin exposure durations.

The label addresses this directly. Section 5.3 warns that all insulins, including Lantus, can cause "life-threatening hypoglycemia" and instructs clinicians to monitor glucose, adjust doses during illness or meal changes, and educate patients on recognition and treatment [3]. FAERS signal strength for hypoglycemia has remained relatively stable year-over-year, suggesting the risk is well-characterized rather than emerging.

The Cancer Controversy: From Signal to Resolution

Perhaps the most consequential FAERS-adjacent signal for insulin glargine was the cancer concern that emerged in 2009. This signal did not originate from FAERS directly but from four observational studies published simultaneously in Diabetologia, with German registry data suggesting a dose-dependent association between insulin glargine and cancer incidence [4].

The biological plausibility rested on glargine's slightly higher affinity for the insulin-like growth factor 1 receptor (IGF-1R) compared to human insulin. IGF-1R signaling promotes cell proliferation. The concern was serious enough that the European Medicines Agency (EMA) launched a formal review, and the FDA issued a communication acknowledging the signal while cautioning against changing therapy based on preliminary data.

The definitive answer came from ORIGIN (Outcome Reduction with an Initial Glargine Intervention), a randomized trial enrolling 12,537 patients with early type 2 diabetes or prediabetes across 573 sites in 40 countries. Participants received either insulin glargine (targeting fasting glucose ≤95 mg/dL) or standard care for a median of 6.2 years. The primary cardiovascular outcomes were neutral. The cancer results were clear: incident cancers occurred in 5.6% of the glargine group versus 5.8% of the standard-care group (HR 0.94, 95% CI 0.77-1.15, P=0.52) [5]. No site-specific cancer showed a significant increase.

Dr. Hertzel Gerstein, principal investigator of ORIGIN, stated: "These results should be reassuring to the millions of patients using insulin glargine. A randomized trial of this size and duration provides far stronger evidence than the observational studies that raised the initial concern."

The FDA updated the Lantus label in 2015 to incorporate ORIGIN data, effectively closing the cancer signal. The EMA reached the same conclusion. This episode remains an instructive case study in how FAERS-type signals can trigger the right investigative response while also generating significant patient anxiety during the interim period [5].

Injection-Site Reactions and Immunogenicity

FAERS data for Lantus contains a consistent low-level signal for injection-site reactions, including lipodystrophy (lipohypertrophy and lipoatrophy), erythema, pruritis, and localized pain. These events are reported across all injectable insulins, not uniquely for glargine.

Lipohypertrophy deserves specific attention because of its clinical impact on absorption. Repeated injection into hypertrophied tissue creates erratic insulin uptake, which can paradoxically increase both hyperglycemia and hypoglycemia risk. A 2016 cross-sectional study of 430 insulin-treated patients found lipohypertrophy prevalence of 37.7%, with affected patients requiring 15 more daily units of insulin on average and experiencing unexplained hypoglycemia four times more frequently [6]. The Lantus label (Section 5.5) advises rotation of injection sites within the same region to reduce this risk [3].

Immunogenicity signals appear in FAERS as "insulin antibody positive" and related terms. The clinical relevance varies. In Lantus clinical trials, 24.1% of patients developed anti-insulin antibodies, but antibody titers correlated poorly with changes in HbA1c or hypoglycemia frequency. True insulin allergy, with systemic reactions, is reported in FAERS at very low rates (fewer than 1 per 10,000 reports). The label includes immunogenicity data in Section 6.1, noting that antibody formation is "highly dependent on the sensitivity and specificity of the assay" and that "comparison of the incidence of antibodies to Lantus with the incidence of antibodies in other studies or to other products may be misleading" [3].

Medication Errors and Device-Related Signals

A distinct FAERS signal category for Lantus involves medication errors, particularly device confusion. The introduction of the SoloSTAR pen device reduced some error types but introduced others. FAERS reports document instances of patients confusing Lantus SoloSTAR with other similarly shaped pen devices (including rapid-acting insulins), administering the wrong insulin type. This is not a pharmacological safety signal but a human-factors issue with real consequences.

The FDA's Safe Use Initiative has flagged insulin pen mix-ups as a priority area. In 2019, ISMP (Institute for Safe Medication Practices) reported that insulin products collectively ranked among the top three drug classes for serious FAERS outcomes, with wrong-product errors contributing substantially [7]. The Lantus label now includes a prominent warning that patients should always verify the insulin label before each injection and never share pens between patients, even with changed needles.

Dose-stacking errors also appear in FAERS, where patients administer a second dose because they forgot or were uncertain about the first. These errors disproportionately affect elderly patients and those with cognitive impairment. Memory-aid pen caps and digital dose-tracking apps represent non-pharmacological interventions that may reduce this signal over time.

Cardiovascular Safety: What ORIGIN Confirmed

Cardiovascular events (myocardial infarction, stroke, cardiovascular death) appear in FAERS data for Lantus, which is expected given that type 2 diabetes itself carries substantial cardiovascular risk. The question was whether insulin glargine independently increased or decreased that risk.

ORIGIN provided the answer. The co-primary cardiovascular endpoint (cardiovascular death, nonfatal MI, or nonfatal stroke) occurred in 2.94 per 100 person-years in the glargine group versus 2.85 in the standard-care group (HR 1.02, 95% CI 0.94-1.11, P=0.63) [5]. The expanded endpoint adding heart failure hospitalization, revascularization, or hospitalization for unstable angina was also neutral (HR 1.04, 95% CI 0.97-1.11).

The American Diabetes Association's Standards of Care now reflect this evidence, positioning basal insulin (including glargine) as cardiovascularly neutral when used for glycemic management [8]. FAERS cardiovascular reports for Lantus are therefore interpreted as disease-related events in a high-risk population rather than drug-attributable signals. Weight gain of approximately 1.6 kg over 6.2 years in ORIGIN participants randomized to glargine was modest and did not translate to excess cardiovascular events.

Comparing FAERS Profiles: Glargine vs. Other Basal Insulins

FAERS allows crude comparisons between insulin products, though prescription volume differences make direct signal comparison unreliable without pharmacoepidemiologic adjustment. Insulin degludec (Tresiba) has shown a lower proportional reporting ratio for severe hypoglycemia compared to glargine in some FAERS analyses, a finding consistent with the SWITCH 2 trial (N=721), which demonstrated 30% lower rates of overall symptomatic hypoglycemia with degludec versus glargine U-100 [9].

Insulin glargine U-300 (Toujeo), a concentrated formulation, generates a partially distinct FAERS profile. The EDITION trials showed fewer nocturnal hypoglycemia events with U-300 versus U-100 glargine, and FAERS data reflects a lower hypoglycemia reporting rate per estimated prescription. However, U-300 requires approximately 10-18% higher daily doses to achieve equivalent glycemic control, which introduces its own considerations for cost and injection volume.

The arrival of biosimilar insulin glargine products (Semglee, approved 2021; Rezvoglar, approved 2021) has added complexity to FAERS signal tracking. The FDA now monitors whether biosimilar safety profiles track the reference product. Early biosimilar FAERS data has not revealed divergent signals, consistent with the FDA's guidance on biosimilar insulin monitoring [10].

Current Label Warnings and Regulatory Status

The most recent Lantus prescribing information (revised 2019) contains no boxed warning. The Warnings and Precautions section (Section 5) lists six key areas [3]:

Never share Lantus KwikPen or SoloSTAR between patients. Hyperglycemia or hypoglycemia with changes in insulin regimen. Hypoglycemia as the most common adverse reaction. Medication errors between insulin products. Hypersensitivity and allergic reactions. And hypokalemia, which can occur with all insulins and is clinically relevant when combined with potassium-lowering drugs.

Section 6.1 reports the most common adverse reactions in clinical trials as hypoglycemia (occurring in 19.2-29.0% of patients across studies), injection-site reactions, lipodystrophy, weight gain, peripheral edema, and allergic reactions [3]. Post-marketing experience (Section 6.2) adds reports of anaphylaxis and localized cutaneous amyloidosis at injection sites.

The Endocrine Society's 2024 clinical practice guideline on type 2 diabetes management recommends basal insulin initiation when HbA1c remains above target despite oral agents and/or GLP-1 receptor agonists, with insulin glargine listed as a first-line basal option [11]. This guideline reflects the cumulative evidence from both pre-market trials and 25 years of post-market surveillance through FAERS and Sentinel.

Dr. Irl Hirsch, professor of medicine at the University of Washington, has noted: "Insulin glargine's safety profile is among the best characterized of any diabetes medication. Two decades of FAERS data and a 12,000-patient randomized outcomes trial give us a level of confidence that newer agents simply haven't had time to accumulate."

Clinicians prescribing Lantus should report suspected adverse events to FDA MedWatch (1-800-FDA-1088 or online) to maintain the quality of ongoing pharmacovigilance.